JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that a preclinical study that is part of its ThermoStem® program has been published in the February issue of the peer-reviewed journal, Stem Cells. A photograph of the Company’s brown fat stem cell scaffold appears prominently on the cover. As previously announced, the newly identified human adult brown fat stem cells discussed in the study have the potential to lead to the development of a cell-based method for the treatment of type 2 diabetes and obesity.
Mark Weinreb, Chief Executive Officer of BRT, said, “We are very excited to have our research published in such a prestigious journal, and are thrilled to be the featured on the cover. We view the publication of research to be potential validation of our approach toward solving the growing problem of obesity and metabolic disease and we are very pleased with the prominent placement of our research.”
As previously announced, the Company’s research demonstrated that functional brown adipose derived stem cells (BADSCs) produced improvements in mice with diet-induced metabolic disorder. The results of the study showed for the first time that a multipotent stem cell population exists in human adult adipose deposits and that this population can be differentiated into metabolically functional brown adipocytes. Brown adipocytes are key cells that are involved in energy homeostasis and metabolism. In humans, loss of brown adipose (fat) activity may account for the lower metabolism often associated with diabetes and obesity. A link to the online publication is http://onlinelibrary.wiley.com/doi/10.1002/stem.1595/abstract.
This study was conducted in collaboration with a team of researchers at the University of Utah School of Medicine.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:
- brtxDISC™ (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient’s own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
- ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
- brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.